Scibase Holding
0.505 SEK +4.34%39 investors are following this company
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
P/E (24e)
-1.76
EV/EBIT (adj.) (24e)
-1.79
P/B (24e)
4.48
Dividend yield-% (24e)
-
Target price
0.32 SEK
Recommendation
Reduce
Updated
3.6.2024
First North Stockholm
SCIB
Daily low / high price
0.48 / 0.505
SEK
Market cap
110.87M SEK
Turnover
38.44K SEK
Volume
79K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Antti Luiro Antti Luiro](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Luiro.jpg)
Antti Luiro
Head of Nordic ER Development, Analyst
Latest videos
Financial calendar
Interim report
2024-08-21
Interim report
2024-11-12
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Gell Group | 11.0 % | 11.0 % |
Avanza Pension | 9.7 % | 9.7 % |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 9.5 | 11.7 | 17.9 | 23.2 | 31.2 | 47.6 | 77.1 | 122.5 |
growth-% | 2.6 % | 23.2 % | 52.6 % | 29.9 % | 34.4 % | 52.5 % | 61.9 % | 58.9 % |
EBITDA | -32.2 | -38.7 | -42.8 | -50.6 | -53.1 | -44.2 | -25.9 | 3.7 |
EBIT (adj.) | -34.8 | -41.6 | -46.4 | -53.9 | -56.4 | -47.2 | -29.1 | 0.3 |
EBIT | -34.8 | -41.6 | -46.4 | -53.9 | -56.4 | -47.2 | -29.1 | 0.3 |
Profit before taxes | -35.0 | -41.8 | -43.2 | -53.9 | -53.3 | -47.7 | -29.6 | -0.2 |
Net income | -35.0 | -41.8 | -43.2 | -53.9 | -53.3 | -47.7 | -29.6 | -0.2 |
EPS (adj.) | -1.12 | -0.67 | -0.63 | -0.50 | -0.29 | -0.22 | -0.13 | -0.00 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -337.7 % | -329.6 % | -239.1 % | -217.5 % | -170.0 % | -92.7 % | -33.5 % | 3.0 % |
EBIT-% (adj.) | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -180.7 % | -99.1 % | -37.7 % | 0.2 % |
EBIT-% | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -180.7 % | -99.1 % | -37.7 % | 0.2 % |
ROE | -88.7 % | -71.0 % | -89.9 % | -158.0 % | -157.3 % | -5,258.7 % | 78.4 % | 0.5 % |
ROI | -88.2 % | -70.7 % | -96.7 % | -158.0 % | -166.5 % | -171.3 % | -75.7 % | 0.4 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (SEK) | 4.48 | 5.36 | 3.71 | 0.83 | 0.51 | 0.51 | 0.51 | 0.51 |
Shares | 54.8 | 68.5 | 68.5 | 119.8 | 219.5 | 219.5 | 219.5 | 219.5 |
Market cap | 245.6 | 366.9 | 253.9 | 99.9 | 110.8 | 110.8 | 110.8 | 110.8 |
Enterprise value | 204.2 | 301.3 | 235.1 | 65.8 | 101.2 | 154.6 | 194.4 | 210.7 |
EV/S | 21.4 | 25.7 | 13.1 | 2.8 | 3.2 | 3.2 | 2.5 | 1.7 |
EV/EBITDA | - | - | - | - | - | - | - | 56.5 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | 841.6 |
EV/EBIT | - | - | - | - | - | - | - | 841.6 |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 5.2 | 5.2 | 10.1 | 2.3 | 4.5 | - | - | - |
P/S | 25.8 | 31.3 | 14.2 | 4.3 | 3.5 | 2.3 | 1.4 | 0.9 |
Dividend yield | ||||||||
Equity ratio | 79.1 % | 82.8 % | 50.6 % | 66.9 % | 47.3 % | -33.8 % | -52.1 % | -35.3 % |
Gearing ratio | -88.4 % | -92.7 % | -74.6 % | -79.2 % | -39.0 % | -190.7 % | -159.1 % | -189.3 % |
Quarter data
Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24e | Q3/24e | Q4/24e | 2024e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 5.1 | 7.2 | 5.8 | 23.2 | 6.1 | 7.3 | 9.1 | 8.7 | 31.2 |
EBITDA | -12.8 | -12.0 | -15.7 | -50.6 | -13.4 | -14.0 | -12.7 | -12.9 | -53.1 |
EBIT | -13.8 | -12.7 | -16.6 | -53.9 | -14.3 | -14.9 | -13.5 | -13.8 | -56.4 |
Profit before taxes | -13.8 | -12.7 | -16.6 | -53.9 | -10.9 | -15.0 | -13.6 | -13.9 | -53.3 |
Net income | -13.8 | -12.7 | -16.6 | -53.9 | -10.9 | -15.0 | -13.6 | -13.9 | -53.3 |
ShowingAll content types
SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order
SciBase ingår samarbete med ett större dermatologinätverk i Los Angeles, Unified Health, och erhåller en första order
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
SciBase välkomnar ny styrelseordförande och avtackar den tidigare
SciBase welcomes new chairman and thanks the former
Årsstämma har hållits i SciBase Holding AB (publ)
Annual general meeting has been held in SciBase Holding AB (publ)
SciBase förstärker USA organisationen med erfaren ledare inom dermatologi
SciBase strengthens the US organization with experienced leader in dermatology
![SciBase Q1´24: Building faster growth takes time](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/f570543d-cd48-45ad-9186-2a8ded34b780.png)
SciBase Q1´24: Building faster growth takes time
![SciBase: Building faster growth takes time](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/546a3302-f056-45d5-9957-11ead5ab01d5.png)